The upgrade from Underweight to Equal-Weight by a major financial institution like Barclays, accompanied by a significant increase in the price target, suggests a positive reassessment of Deciphera Pharmaceuticals' market position, financial health, or growth prospects. This is likely to be viewed positively by the market, potentially leading to an increase in investor confidence and a rise in the stock price in the short term.